Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosfocreatine SCHEMBL65425 | 1.00 | MVD (0.44) | MVD | |
| Fosfocreatine SCHEMBL2124030 | 1.00 | MVD (0.44) | MVD | |
| Fosfocreatine SCHEMBL2635002 | 0.98 | MVD (0.42) | MVD | |
| Fosfocreatine SCHEMBL5248692 | 0.92 | MVD (0.39) | MVD | |
| Fosfocreatine SCHEMBL9075223 | 0.92 | MVD (0.39) | MVD | |
| Fosfocreatine SCHEMBL453327 | 0.90 | MVD (0.38) | MVD | |
| Fosfocreatine SCHEMBL29526710 | 0.89 | MVD (0.37) | MVD | |
| Fosfocreatine SCHEMBL29749874 | 0.82 | MVD (0.40) | MVD | |
| Fosfocreatine SCHEMBL1640494 | 0.81 | MVD (0.38) | MVD | |
| Fosfocreatine SCHEMBL30031412 | 0.81 | MVD (0.38) | MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331042-B2 | Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions | ADAMS VOLKER (DE) | 2025-06-17 | — | — | US | disclosed |
| US-12227778-B2 | Cell-free expression system having novel inorganic polyphosphate-based energy regeneration | NATURE'S TOOLBOX, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| EP-3312278-B1 | PROTEIN EXPRESSION METHOD | UNIV NAGOYA NAT UNIV CORP (JP) | 2024-12-04 | — | — | EP | disclosed |
| EP-4013497-B1 | COMPOUNDS SUITABLE FOR THE TREATMENT AND PROPHYLAXIS OF MUSCLE WASTING AND OTHER CONDITIONS | ADAMS VOLKER (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-20230285338-A9 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | WASHINGTON UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20220324852-A1 | COMPOUNDS SUITABLE FOR THE TREATMENT AND PROPHYLAXIS OF MUSCLE WASTING AND OTHER CONDITIONS | ADAMS VOLKER (DE) | 2022-10-13 | — | — | US | disclosed |
| US-20220289809-A1 | USE OF RELAXIN TO TREAT ATRIAL FIBRILLATION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-09-15 | — | — | US | disclosed |
| EP-4013497-A1 | COMPOUNDS SUITABLE FOR THE TREATMENT AND PROPHYLAXIS OF MUSCLE WASTING AND OTHER CONDITIONS | Adams, Volker (DE) | 2022-06-22 | — | — | EP | disclosed |
| EP-3562940-B1 | CELL-FREE EXPRESSION SYSTEM HAVING NOVEL INORGANIC POLYPHOSPHATE-BASED ENERGY REGENERATION | NATURES TOOLBOX INC (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20210393563-A1 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324852-A1 | COMPOUNDS SUITABLE FOR THE TREATMENT AND PROPHYLAXIS OF MUSCLE WASTING AND OTHER CONDITIONS | MYOF, TNNC1, CPT1B | MVD 3344/4885 |
| US-20210393563-A1 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | CHRNB2, PSEN2, CX3CR1 | MVD 3547/4885 |
| US-20230285338-A9 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | CX3CR1, CD68, FYN | MVD 2423/4885 |
| US-12331042-B2 | Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions | MYOF, TNNC1, CPT1B | MVD 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.